93 related articles for article (PubMed ID: 18785112)
1. Fli-1 expression in malignant melanoma.
Torlakovic EE; Slipicevic A; Flørenes VA; Chibbar R; DeCoteau JF; Bilalovic N
Histol Histopathol; 2008 Nov; 23(11):1309-14. PubMed ID: 18785112
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of FLI-1 in melanoma.
Ramani N; Aung PP; Hwu WJ; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Prieto VG; Torres-Cabala CA
J Cutan Pathol; 2017 Sep; 44(9):790-793. PubMed ID: 28605142
[TBL] [Abstract][Full Text] [Related]
3. Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
Mhawech-Fauceglia P; Herrmann FR; Bshara W; Odunsi K; Terracciano L; Sauter G; Cheney RT; Groth J; Penetrante R; Mhawech-Fauceglia P
J Clin Pathol; 2007 Jun; 60(6):694-700. PubMed ID: 16917000
[TBL] [Abstract][Full Text] [Related]
4. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression.
Bilalovic N; Sandstad B; Golouh R; Nesland JM; Selak I; Torlakovic EE
Mod Pathol; 2004 Oct; 17(10):1251-8. PubMed ID: 15205682
[TBL] [Abstract][Full Text] [Related]
5. Immunolabeling for p16, WT1, and Fli-1 in the assignment of growth phase for cutaneous melanomas.
Strickler AG; Schaefer JT; Slingluff CL; Wick MR
Am J Dermatopathol; 2014 Sep; 36(9):718-22. PubMed ID: 25062258
[TBL] [Abstract][Full Text] [Related]
6. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
[TBL] [Abstract][Full Text] [Related]
7. [Characteristics of ERG, Fli-1, CD34, CD31 and FⅧRAg expression in hepatic malignant vascular tumors].
Wang ZB; An XJ; Deng JF; Liu JH; Shi HY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):760-763. PubMed ID: 29136688
[No Abstract] [Full Text] [Related]
8. Maspin expression in the invasive margin of primary melanomas may reflect an aggressive tumor phenotype.
Pföhler C; Knöpflen T; Körner R; Vogt T; Rösch A; Müller CS
J Dtsch Dermatol Ges; 2013 Oct; 11(10):993-9. PubMed ID: 23848940
[TBL] [Abstract][Full Text] [Related]
9. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
Lee AF; Hayes MM; Lebrun D; Espinosa I; Nielsen GP; Rosenberg AE; Lee CH
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):233-8. PubMed ID: 21084965
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of adenylate cyclase-associated protein 2 is a novel prognostic marker in malignant melanoma.
Masugi Y; Tanese K; Emoto K; Yamazaki K; Effendi K; Funakoshi T; Mori M; Sakamoto M
Pathol Int; 2015 Dec; 65(12):627-34. PubMed ID: 26374196
[TBL] [Abstract][Full Text] [Related]
11. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
13. Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma.
Soltani MH; Pichardo R; Song Z; Sangha N; Camacho F; Satyamoorthy K; Sangueza OP; Setaluri V
Am J Pathol; 2005 Jun; 166(6):1841-50. PubMed ID: 15920168
[TBL] [Abstract][Full Text] [Related]
14. Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia.
Cui JW; Vecchiarelli-Federico LM; Li YJ; Wang GJ; Ben-David Y
Leukemia; 2009 Jul; 23(7):1311-9. PubMed ID: 19282832
[TBL] [Abstract][Full Text] [Related]
15. Friend leukemia virus integration-1 (FLI-1) expression in gastrointestinal stromal tumors.
Kaygusuz G; Kuzu I
Turk J Gastroenterol; 2009 Jun; 20(2):83-6. PubMed ID: 19530039
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
17. Friend leukemia virus integration 1 activates the Rho GTPase pathway and is associated with metastasis in breast cancer.
Song W; Li W; Li L; Zhang S; Yan X; Wen X; Zhang X; Tian H; Li A; Hu JF; Cui J
Oncotarget; 2015 Sep; 6(27):23764-75. PubMed ID: 26156017
[TBL] [Abstract][Full Text] [Related]
18. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
19. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
